Hepatology · Article 192

Who Still Needs HCC Surveillance After HCV Eradication?

HCC surveillance after HCV requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

HCC surveillance after HCV clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

HCC surveillance after HCV: practical clinical approach

This page focuses on HCC surveillance after HCV with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for HCC surveillance after HCV

Clinical takeaway: For HCC surveillance after HCV, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Patients who had cirrhosis before HCV cure should continue HCC surveillance indefinitely unless competing illness makes surveillance futile. AASLD guidance recommends liver ultrasound with or without AFP every six months. Routine surveillance is not recommended for patients without cirrhosis solely because they previously had HCV, although individual risk assessment may be appropriate when fibrosis staging is uncertain or additional liver disease is present.

SVR reduces but does not abolish risk

The relative HCC risk falls substantially after cure, but cirrhotic patients remain above accepted surveillance thresholds.

Fibrosis staging before treatment matters

If the original stage was uncertain, review elastography, platelets, imaging and clinical history rather than assuming low risk.

New liver injury can preserve risk

Alcohol, MASLD and HBV can sustain fibrosis progression after HCV is eradicated.

Practical clinical algorithm

1. Determine whether cirrhosis was present before cure.

2. If cirrhosis, continue ultrasound ± AFP every six months.

3. If clearly noncirrhotic, do not perform routine HCC surveillance solely for prior HCV.

4. Address ongoing alcohol/metabolic liver injury.

5. Reassess patients whose original fibrosis stage was uncertain.

Common mistakes to avoid

Stopping surveillance because HCV RNA is negative.
Starting surveillance for everyone with prior HCV.
Using annual rather than six-month surveillance in cirrhosis.
Ignoring new MASLD/alcohol risk.
Using a low post-SVR FIB-4 alone to ‘erase’ established cirrhosis.

Trainee takeaway

Curing HCV removes the viral driver; it does not erase established cirrhotic cancer risk.

Frequently asked questions

How often is surveillance performed?

Every six months.

Does fibrosis regression allow surveillance to stop?

Current guidance does not routinely support stopping surveillance in patients with established cirrhosis.

What test is used?

Ultrasound, generally with or without AFP.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Practice Review in Hepatopancreaticobiliary Diseases and Nutrition. CAPstone Academic Publishers; 2014.

3. AASLD-IDSA HCV Guidance. Follow-Up After SVR.

4. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of HCC. Hepatology. 2023.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions